BURLINGAME, CALIFORNIA, UNITED STATES, December 29, 2022 /EINPresswire.com/ -- Coherent Market Insights released a 150+ page Monovaccine (Epstein - Barr virus) Market report. Human B cells get infected by the Epstein-Barr virus (EBV), which then spreads the infection across the entire reticuloendothelial system (RES). Multiple sclerosis, celiac disease, systemic lupus erythematosus, juvenile idiopathic arthritis, inflammatory bowel disease, rheumatoid arthritis, and type 1 diabetes are only a few of the autoimmune diseases that have been linked to the virus. Epstein-Barr virus has been associated in numerous studies to lupus and a few types of lymphatic cancer. For instance, the Cincinnati Children's Hospital Medical Center research from 2018 states that having the Epstein-Barr virus (EBV) infection doubles the likelihood of getting multiple sclerosis. B-cells are used by the body to manufacture antibodies to fend off external invaders like viruses and bacteria when they come into contact with the body.

The global Monovaccine (Epstein - Barr virus) market size is expected to reach US$ 2.0 billion by 2028, growing at a CAGR of 6.8% from 2022 to 2028, according to a new study conducted by Coherent Market Insights, Inc.

Ask Us to Get Your Request For Sample Report on “Monovaccine (Epstein - Barr virus) Market” Covering TOC and Regional Analysis :
https://www.coherentmarketinsights.com/insight/request-sample/2002

𝗧𝗵𝗲 𝗠𝗮𝗷𝗼𝗿 𝗣𝗹𝗮𝘆𝗲𝗿𝘀 𝗣𝗿𝗼𝗳𝗶𝗹𝗲𝗱 𝗜𝗻 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁 𝗜𝗻𝗰𝗹𝘂𝗱𝗲: AstraZeneca Plc, Aurobindo Pharma Ltd., Bavarian Nordic AS, China National Pharmaceutical Group Corp., Dynavax Technologies Corp., GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Moderna Inc., Pfizer Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Valneva SE, and VBI Vaccines Inc.

The researchers revealed that virus-derived EBNA2 transcription factor binds to several spots in the human genome that are linked to above mentioned diseases. Moreover, EBV is linked with several human cancers such as Burkitt’s lymphoma, nasopharyngeal carcinoma, and post-transplant lymphoproliferative disorder. However, the exact reason for EBV leading to different types of cancers is currently being studied by various researchers. For instance, according to the study published in Gynecologic Oncology Journal, 2017, researchers from the Federal University of Cariri stated that cervical carcinoma was four times more prevalent among EBV positive women than in women without EBV infection. This indicated that EBV infection increases the risk of cervical carcinoma.

The Monovaccine (Epstein - Barr virus) Market Research Report also provides opportunities for business owners to exploit through the use of relevant approaches. The study’s prospects assist stakeholders and report purchasers in properly planning their investments and augment their profits.

Buy the Latest Version of the Report Available Now at UP TO 25% off Discounted Pricing :

Single User License : https://www.coherentmarketinsights.com/insight/buy-now/2002

Multi Users License : https://www.coherentmarketinsights.com/insight/buy-now/2002

Corporate Users License : https://www.coherentmarketinsights.com/insight/buy-now/2002

Note: Special discounted pricing is only applicable for direct purchase through website. In case of customization, discount would be subject to scope and coverage of the report.

𝗗𝗲𝘁𝗮𝗶𝗹𝗲𝗱 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻:

By Application:

• Mononucleosis
• Endemic Burkitt’s lymphoma
• Hodgkin’s lymphoma
• Gastric carcinomas
• Multiple sclerosis
• Nasopharyngeal Carcinoma

By Type
• Meningococcal vaccine
• Japanese encephalitis vaccine
• Hepatitis vaccine
• Yellow fever vaccine
• Others

𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀:

The following regions are examined in terms of production, consumption, revenue, market share, growth rate, and projections in the report:

– North America (United States, Canada and Mexico)

– Europe (Germany, UK, France, Italy, Russia and Spain etc.)

– Asia Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)

– South America (Brazil, Argentina and Chile etc.)

– Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)

Request PDF Brochure with Latest Insights :
https://www.coherentmarketinsights.com/insight/request-pdf/2002

Key Highlights of the Monovaccine (Epstein - Barr virus) Market:

✅ Market intelligence to enable decision making

✅ Market estimates and forecast period 2022 to 2028

✅ Growth opportunities and Future Scope

✅ segment details and regional revenue forecasts for market assessment

✅ Competition strategy and market size analysis

✅ Product innovation listing for you to stay ahead of the curve

✅ Market report in PDF, PPT and online dashboard versions

Frequently Asked Questions About This Report

① Which segment accounted for the largest Monovaccine (Epstein - Barr virus) market share?

② Who are the key players in Monovaccine (Epstein - Barr virus) market?

③ What are the factors driving the Monovaccine (Epstein - Barr virus) market?

④ How big is the Monovaccine (Epstein - Barr virus) market?

⑤ What is the Monovaccine (Epstein - Barr virus) market growth?

Related Reports -

Single use bioreactor market : https://www.coherentmarketinsights.com/market-insight/single-use-bioreactor-market-5358

Us influenza vaccines market : https://www.coherentmarketinsights.com/market-insight/us-influenza-vaccines-market-1127

Protein engineering market : https://www.coherentmarketinsights.com/market-insight/protein-engineering-market-5272

Conjugate vaccine market : https://www.coherentmarketinsights.com/market-insight/conjugate-vaccine-market-2697

Mr.Shah
Coherent Market Insights
+ 12067016702
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.